< Key Hightlight >

US and China Pre-Treatment Kit for Molecular Diagnosis of Sepsis Market Research Report Forecast to 2030

Market Overview

The growth of the pre-treatment kit for molecular diagnosis of sepsis market is attributed to the Rising incidence of sepsis, advancements in molecular diagnostic technologies, and increasing investment in research and development and increasing geriatric population. However, limited awareness and education is anticipated to hamper market growth. 

A pre-treatment kit refers to a collection of components, reagents, and materials used in the initial steps of a diagnostic or analytical process. It is specifically designed to prepare a sample for further analysis or testing. In the context of molecular diagnosis of sepsis, a pre-treatment kit would include items necessary for the collection, preservation, and processing of patient samples to facilitate the accurate and efficient detection of sepsis-causing pathogens or related markers through molecular diagnostic techniques such as PCR or nucleic acid amplification.

The expected growth in the market can be attributed to the growing prevalence of sepsis and increasing geriatric population. However, the market is also held back by a lack of skilled personnel. Nevertheless, it is anticipated that the growing public-private funding for sepsis diagnostic research activities will create lucrative opportunities for the players operating in the US & China pre-treatment kit for molecular diagnosis of sepsis market.

Market Segmentation

Based on product, the US & China pre-treatment kits for molecular diagnosis of sepsis market have been segmented into automated extraction equipment and multi-well chamber construction kits. The multi-well chamber construction kits segment dominated the market in 2022, while the automated extraction equipment segment is projected to be the fastest-growing during the forecast period, 2023–2030. 

Regional Analysis

The rising incidence of sepsis, the increasing burden of hospital-acquired infections, a growing number of pneumonia cases, the increase in the number of sepsis procedures, and an increase in funding for sepsis-related research activities are the major factors driving the growth of the US pre-treatment kits for molecular diagnosis of sepsis market. 

In China, sepsis is a leading cause of illness and mortality. Sepsis is common in this country due to its vast population and diverse healthcare system. The illness causes a significant strain on healthcare systems, resulting in more hospital admissions, longer hospital stays, and higher healthcare expenses. Additionally, however, in China, various obstacles impede appropriate sepsis care. Limited awareness of sepsis symptoms and early warning signals among healthcare personnel and the public contributes to delayed diagnosis. Furthermore, the lack of standardized methods for sepsis management, as well as variable adherence to existing standards, provide substantial challenges. 

Major Players

The key market players are F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc (US), Abbott (US), Siemens Medical Solutions USA, Inc (Germany), and Qiagen (Germany). Other key players contributing to the market growth include T2 Biosystems, Inc (US), Luminex Corporation (US), Bioneer Corporation (South Korea), Cepheid (US), and BioMérieux SA (France).